MOLECULAR PHARMACOLOGY (USA) LTD. Financial Statements (2026 and earlier)
Company Profile
| Business Address |
DRUG DISCOVERY RESEARCH CENTRE PERTH, WESTERN AUSTRALIA, 00000 |
| State of Incorp. | NV |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2014 MRQ | 6/30/2014 | 6/30/2013 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 2,378 | 7,046 | |||
| Cash and cash equivalent | 2,378 | 7,046 | |||
| Receivables | 6,493 | 5,070 | |||
| Other undisclosed current assets | 97 | 140 | |||
| Total current assets: | 8,968 | 12,256 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 97 | 140 | |||
| Total noncurrent assets: | 97 | 140 | |||
| TOTAL ASSETS: | 9,065 | 12,396 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 34,526 | 21,628 | |||
| Accounts payable | 34,526 | 21,628 | |||
| Total current liabilities: | 34,526 | 21,628 | |||
| Noncurrent Liabilities | |||||
| Other undisclosed liabilities | 2,207,296 | 2,044,501 | |||
| Total liabilities: | 2,241,822 | 2,066,129 | |||
| Equity | |||||
| Equity, attributable to parent, including: | (2,232,854) | (2,053,873) | |||
| Common stock | 111,554 | 111,554 | |||
| Additional paid in capital | 106,707 | 106,707 | |||
| Accumulated deficit | (2,178,876) | (2,061,948) | |||
| Other undisclosed equity, attributable to parent | (272,239) | (210,186) | |||
| Total equity: | (2,232,854) | (2,053,873) | |||
| TOTAL LIABILITIES AND EQUITY: | 8,968 | 12,256 | |||
Income Statement (P&L) (USD)
| 9/30/2014 TTM | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|
| Operating expenses | (6,875) | (1,395) | ||
| Other undisclosed operating loss | (110,053) | (207,682) | ||
| Operating loss: | (116,928) | (209,077) | ||
| Loss from continuing operations: | (116,928) | (209,077) | ||
| Loss before gain (loss) on sale of properties: | (116,928) | (209,077) | ||
| Net loss: | (116,928) | (209,077) | ||
| Other undisclosed net loss attributable to parent | (823) | |||
| Net loss available to common stockholders, diluted: | (116,928) | (209,900) | ||
Comprehensive Income (USD)
| 9/30/2014 TTM | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|
| Net loss: | (116,928) | (209,077) | ||
| Comprehensive loss: | (116,928) | (209,077) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (62,053) | 235,063 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (178,981) | 25,986 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.